The hemodynamics of erection and the pharmacotherapies of erectile dysfunction

Arnold Melman, George J. Christ

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The past few years have been witness to a sea of change in understanding the diagnosis and treatment of erectile dysfunction. In the wake of Viagra, effective orally administered therapies are now the expected gold standard. Currently available therapies include both peripherally (at the level of the penis) and centrally (brain, e.g., hypothalamic nuclei) acting compounds. When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. However, all forms of pharmacotherapy have the lowest efficacy and greatest side effect profiles (including cardiovascular events) in the patients that need the therapy most, that is, those with relatively severe and longstanding erectile dysfunction. The newer generation of pharmacotherapies, which will likely include gene therapy techniques as well, will therefore have to target this latter group. Improved mechanism-based, perhaps patient-specific therapies are foreseen that will dramatically increase the number of patients seeking treatment, as well as the quality of their lives.

Original languageEnglish (US)
Pages (from-to)252-264
Number of pages13
JournalHeart Disease
Volume4
Issue number4
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Erectile Dysfunction
Hemodynamics
Drug Therapy
Therapeutics
Penis
Genetic Therapy
Injections
Brain

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. / Melman, Arnold; Christ, George J.

In: Heart Disease, Vol. 4, No. 4, 07.2002, p. 252-264.

Research output: Contribution to journalArticle

Melman, A & Christ, GJ 2002, 'The hemodynamics of erection and the pharmacotherapies of erectile dysfunction', Heart Disease, vol. 4, no. 4, pp. 252-264.
Melman, Arnold ; Christ, George J. / The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. In: Heart Disease. 2002 ; Vol. 4, No. 4. pp. 252-264.
@article{4a782745266a4ce79a118f5e9f528c60,
title = "The hemodynamics of erection and the pharmacotherapies of erectile dysfunction",
abstract = "The past few years have been witness to a sea of change in understanding the diagnosis and treatment of erectile dysfunction. In the wake of Viagra, effective orally administered therapies are now the expected gold standard. Currently available therapies include both peripherally (at the level of the penis) and centrally (brain, e.g., hypothalamic nuclei) acting compounds. When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. However, all forms of pharmacotherapy have the lowest efficacy and greatest side effect profiles (including cardiovascular events) in the patients that need the therapy most, that is, those with relatively severe and longstanding erectile dysfunction. The newer generation of pharmacotherapies, which will likely include gene therapy techniques as well, will therefore have to target this latter group. Improved mechanism-based, perhaps patient-specific therapies are foreseen that will dramatically increase the number of patients seeking treatment, as well as the quality of their lives.",
author = "Arnold Melman and Christ, {George J.}",
year = "2002",
month = "7",
language = "English (US)",
volume = "4",
pages = "252--264",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The hemodynamics of erection and the pharmacotherapies of erectile dysfunction

AU - Melman, Arnold

AU - Christ, George J.

PY - 2002/7

Y1 - 2002/7

N2 - The past few years have been witness to a sea of change in understanding the diagnosis and treatment of erectile dysfunction. In the wake of Viagra, effective orally administered therapies are now the expected gold standard. Currently available therapies include both peripherally (at the level of the penis) and centrally (brain, e.g., hypothalamic nuclei) acting compounds. When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. However, all forms of pharmacotherapy have the lowest efficacy and greatest side effect profiles (including cardiovascular events) in the patients that need the therapy most, that is, those with relatively severe and longstanding erectile dysfunction. The newer generation of pharmacotherapies, which will likely include gene therapy techniques as well, will therefore have to target this latter group. Improved mechanism-based, perhaps patient-specific therapies are foreseen that will dramatically increase the number of patients seeking treatment, as well as the quality of their lives.

AB - The past few years have been witness to a sea of change in understanding the diagnosis and treatment of erectile dysfunction. In the wake of Viagra, effective orally administered therapies are now the expected gold standard. Currently available therapies include both peripherally (at the level of the penis) and centrally (brain, e.g., hypothalamic nuclei) acting compounds. When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. However, all forms of pharmacotherapy have the lowest efficacy and greatest side effect profiles (including cardiovascular events) in the patients that need the therapy most, that is, those with relatively severe and longstanding erectile dysfunction. The newer generation of pharmacotherapies, which will likely include gene therapy techniques as well, will therefore have to target this latter group. Improved mechanism-based, perhaps patient-specific therapies are foreseen that will dramatically increase the number of patients seeking treatment, as well as the quality of their lives.

UR - http://www.scopus.com/inward/record.url?scp=0036637599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036637599&partnerID=8YFLogxK

M3 - Article

C2 - 12147185

AN - SCOPUS:0036637599

VL - 4

SP - 252

EP - 264

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 4

ER -